Cyxone has put intense focus on the development of lead candidate rabeximod - an immunomodulatory treatment for rheumatoid arthritis. The company has now produced important research results that provide a more detailed insight into the drug candidate's mechanism of action. The company's CEO Carl-Magnus Högerkorp tells us more in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/01/cyxone-identifies-target-protein-for-rabeximod/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/cyxone/r/biostock--cyxone-identifies-target-protein-for-rabeximod,c3910722

(c) 2024 Cision. All rights reserved., source Press Releases - English